Veracyte, Inc. announced today that new findings from six studies reinforcing the "real world" performance of the next-generation Afirma Genomic Sequencing Classifier and the Afirma Xpression Atlas in thyroid cancer diagnosis were presented at the 88th Annual Meeting of the American Thyroid Association. The meeting is being held October 3-7 in Washington, D.C.